Results 191 to 200 of about 339,808 (204)

Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis. [PDF]

Lancet Infect Dis
Garcia Quesada M, Peterson ME, Bennett JC, Hayford K, Zeger SL, Yang Y, Hetrich MK, Feikin DR, Cohen AL, von Gottberg A, van der Linden M, van Sorge NM, de Oliveira LH, de Miguel S, Yildirim I, Vestrheim DF, Verani JR, Varon E, Valentiner-Branth P, Tzanakaki G, Sinkovec Zorko N, Setchanova LP, Serhan F, Scott KJ, Scott JA, Savulescu C, Savrasova L, Reyburn R, Oishi K, Nuorti JP, Napoli D, Mwenda JM, Muñoz-Almagro C, Morfeldt E, McMahon K, McGeer A, Mad'arová L, Mackenzie GA, Eugenia León M, Ladhani SN, Kristinsson KG, Kozakova J, Kleynhans J, Klein NP, Kellner JD, Jayasinghe S, Ho PL, Hilty M, Harker-Jones MA, Hammitt LL, Grgic-Vitek M, Gilkison C, Gierke R, French N, Diawara I, Desmet S, De Wals P, Dalby T, Dagan R, Corcoran M, Colzani E, Chanto Chacón G, Castilla J, Camilli R, Ang M, Ampofo K, Almeida SCG, Alarcon P, O'Brien KL, Deloria Knoll M, PSERENADE Team.   +70 more
europepmc   +1 more source

Long-term survival after invasive pneumococcal disease – a matched cohort study using electronic health records in England

Suffel A, Abdullahi F, Barry E, Walker J, Andrews N, Amin-Chowdhury Z, Ladhani SN, Grint D, McDonald HI, Douglas I, Mansfield KE, Parker EP.   +11 more
europepmc   +1 more source

Correction to: Searching for Immunocompromising Conditions in Low-risk Adults After Invasive Pneumococcal Disease: An Opportunity to Uncover Multiple Myeloma Early. [PDF]

Open Forum Infect Dis
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era.

Clinical Infectious Diseases, 2020
BACKGROUND Introduction of pneumococcal conjugate vaccines (PCVs) has shown a marked reduction in the disease caused by vaccine serotypes in children providing herd protection to the elderly group.
S. de Miguel, Mirian Domenech, F. González-Camacho, Julio Sempere, D. Vicioso, J. Sanz, Luis García Comas, C. Ardanuy, A. Fenoll, J. Yuste   +9 more
semanticscholar   +1 more source

Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence

Expert Review of Vaccines, 2021
Introduction: Routine pneumococcal vaccination for adults aged ≥60 or ≥65 years and those with underlying at-risk and high-risk conditions is recommended in many countries.
M. Niederman, Temitope A Folaranmi, U. Buchwald, L. Musey, A. Cripps, Kelly D Johnson   +5 more
semanticscholar   +1 more source

Predictors of mortality in invasive pneumococcal disease: a meta-analysis

Expert Review of Anti-Infective Therapy, 2020
Objectives To assess risk factors for mortality in invasive pneumococcal disease (IPD). Methods We conducted a systemic literature search in January 2019. The main outcome measure included death within 30 days after diagnosis of IPD.
T. Demirdal, Pınar Sen, B. Emir
semanticscholar   +1 more source

Changes in invasive pneumococcal disease spectrum after 13 valent pneumococcal conjugate vaccine implementation.

Clinical Infectious Diseases, 2019
BACKGROUND Pneumococcal conjugate vaccine (PCV) implementation has led to a sharp decrease in invasive pneumococcal disease (IPD) due to the reduction in PCV serotypes (VTs).
C. Levy, E. Varon, N. Ouldali, S. Béchet, S. Bonacorsi, R. Cohen   +5 more
semanticscholar   +1 more source